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We present the case of a 27 year old woman with widely disseminated metastatic adenocarcinoma
of the lung who outlived stage IV diagnosis of NSCLC by more than 4 years. Based on rebiopsy and
molecular diagnostics of oncogene dependency, appropriately targeted therapies were successfully
employed up to a ﬁfth line oral monotherapy with the ErbB family blocker afatinib for a ﬁnal 11
months. We stress the importance of rebiopsies, the corresponding selection of targeted therapies,
and the observed gain in quality of live even in end stage disease.
& 2013 The Authors. Published by Elsevier Ltd. All rights reserved.1. Introduction
Although well established by now, treatment of lung cancer
beyond the ﬁrst therapy line(s) has only been a developmentThe Authors. Published by Elsevi
.07.001
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rcial use, distribution, and
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458 2311;
n.deof the very recent years. In 2004, the ASCO guidelines stated
that “there is no current evidence that either conﬁrms or
refutes that second-line chemotherapy improves survival in
nonresponding or progressing patients with advanced NSCLC.”
[1] Meanwhile, with the arrival of tyrosine kinase inhibitors
(TKIs) which interfere with the signaling pathway of the
epidermal growth factor receptor (EGFR), treatment options
have expanded, and even more versatile drugs are about to
approach the market. Selected patients have already proﬁted
from these drugs and experienced extended treatment options
beyond conventional dead ends. The choice of therapy for
lung cancer patients who are eligible for treatment with oral
EGFR-TKI vs. conventional chemotherapy should be based on
evidence from molecular pathology rather than on clinical
criteria [2]. However, even though sensitizing mutations in theer Ltd. All rights reserved.
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J. Stoehlmacher-Williams et al.2gene coding for EGFR are associated with higher response
rates to EGFR-TKI therapies and prolonged progression-free
survival, in the end resistant mutants prevail through cellular
survival pressure. The most frequent single mutation asso-
ciated with secondary resistance to ﬁrst generation EGFR-TKIs
such as erlotinib and geﬁtinib is the point mutation T790M in
exon 20 of the EGFR gene, coding for the tyrosine kinase
domain and thus extremely sensitive to alterations [3]. The
ErbB-family blocker afatinib is a drug that binds covalently to
the ATP-binding sites of EGFR (Cys797), HER2 (Cys805) and
ErbB4 (Cys 803) [4]. The covalent binding mode allows afatinib
greater occupancy of the ATP-binding site than reversible
inhibitors, providing the ability to inhibit EGFR T790M in pre-
clinical models [4]. Correspondingly, drugs like afatinib may be
an alternative for tumors harboring de novo or acquired
T790M, since an acquired resistance does not make EGFR
signaling redundant, as Sequist et al. observed [5].
We report here the case of a young woman with non-small
cell lung cancer whose patient history showed a typical
series of mutations, and how her therapy was tailored based
on molecular evidence.Fig. 1 (A) Detail of the forward sequencing reaction of exon 19
showing the deletion c.2236_2250del leading to p.E746_A750del.
(B) Detail of the forward sequencing reaction of exon 20 showing
the point mutation c.2369C4T leading to p.T790M. Mutated
nucleotides are marked by open boxes.2. Case presentation
The patient was ﬁrst diagnosed with non-small cell lung
cancer in May 2007, at 27 years of age. The initial PET-CT
showed a 3 cm tumor in the right middle lobe with connec-
tion to the pleura and pleural effusion on this site of the
lung. No affected lymph nodes were detected. However, the
tumor had already spread to the bone and metastases were
detected in the spine. A TTF-1 positive adenocarcinoma of
the lung was diagnosed by CT guided biopsy of the mass in
the lung. The pleural effusion also contained malignant cells
of a TTF-1 positive adenocarcinoma. In addition, a sus-
pected breast cancer was in fact veriﬁed as another
metastasis of the lung tumor after biopsy and histological
analysis of a mass in the left breast.
This young woman had never smoked, nor was there any
evidence of cancer in the family history, yet the tumor had
already metastasized beyond curative treatment options at
the time of diagnosis.
As ﬁrst-line palliative chemotherapy she received pacli-
taxel and carboplatin for 6 months, resulting in a partial
remission lasting for over 3 months. From January to
February 2008 she was treated with pemetrexed, but the
tumor progressed further. At this point molecular analysis of
the initial tumor sample identiﬁed an activating mutation in
exon 19 of the gene coding for the EGF receptor (Fig. 1A),
but no other relevant mutations within the EGFR gene were
identiﬁed in that Sanger analysis.
Erlotinib was started in February 2008 and continued
until December 2009, when, after 22 months, the disease
progressed again and a tumor re-biopsy was taken. Besides
the activating mutation in exon 19 of the EGFR gene it now
revealed a secondary T790M point mutation in exon 20,
conferring resistance to erlotinib. Sanger Sequencing results
of this analysis are presented in Fig. 1B.
Correspondingly, in January 2010 another palliative che-
motherapy consisting of gemcitabine and cisplatin was
initiated. Due to neurotoxicity (tinnitus), the platinum compo-
nent was switched after 1 month to carboplatin, which wasbetter tolerated and kept up for 4 months. Best tumor response
was partial remission, and the regimen was ﬁnished as planned
in May 2010.
In July 2010, the patient experienced severe thoracic
pain, shortness of breath, and analgesia refractory head-
aches. Complete tumor restaging including MRI and CT
imaging was performed. Besides the dissemination in lung,
there was a pericardial effusion that had to be drained and
treated by pericardial instillation of mitoxantrone. Both
metastases in the thoracic vertebrae had not progressed,
nor had the tumor grown at or near the primary sites.
However, the headaches had been caused by disseminated
brain metastases, which were treated with palliative 2D
irradiation of the whole brain with a total dose of 30 Gy.
Based on the molecular histopathology with the activat-
ing mutation in exon 19 and the T790M mutation, the
patient was subsequently included into a compassionate
use program of the ErbB-family blocker afatinib, starting on
50 mg once daily. Due to diarrhea, the dose was reduced
after 4 weeks to 40 mg, which was tolerated very well, the
only side effect being mild rash (grade 1).
Further tumor stagings were performed 2 months and
5 months after start of the oral ﬁfth-line therapy with
afatinib and conﬁrmed stable disease. The patient herself
reported feeling well, had no complaints, felt full of energy,
and was even able to spend and enjoy holidays.
By the end of June 2011, however, 11 months after
starting afatinib, another clinical progression occurred.
There were pleural effusions again and axillary lymph nodes
were palpable. From those lymph nodes, new samples were
taken and analyzed. The analyses conﬁrmed the earlier
results, revealing both T790M in exon 20 of the EGFR gene
Fig. 2 (A) FISH analysis of the lymph node metastasis after ﬁfth-line oral therapy. By counting 60 tumor cell nuclei, a ratio of 226
c-Met signals (green) to 222 chromosome 7 copies (CEN7, orange) was found with 50% of tumor cells harboring ≥4 c-Met copies.
According to the Colorado scoring system which is also applicable to c-Met, this result was considered positive (“high polysomy”).
Re-analysis of a preserved previous tumor sample conﬁrmed that c-Met had not been ampliﬁed before. (B) Previous tumor sample
without relevant increase in c-Met gene copies: 187 c-Met and 187 CEN7 copies were counted in 60 tumor cells (cell block of a
previous cytology sample) and that this new genetic lesion had occurred in parallel to the clinical resistance to afatinib. All other
oncogenes assessed (K-RAS, B-RAF, PIK3CA) were still wild type. The patient died 4 weeks later from respiratory complications. (For
interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
3Case report of afatinib in resistant NSCLCand a deletion which has been associated with increased
sensitivity to EGFR-TKI [6] in exon 19 of the same gene.
Fluorescence in situ hybridization (FISH)-testing revealed
ampliﬁcation of the oncogene c-Met (Fig. 2). In contrast,
retrospective analyses of the former tumor samples did not
show an ampliﬁcation of the oncogene c-Met.3. Discussion
This case shows some practical evidence for mutation
development in a series. First, there was the primary
sensitizing mutation on exon 19, indicating susceptibility
to EGFR-TKI. Then, following treatment with EGFR-TKI,
secondary resistance resulted from development of the
point mutation T790M, but the tumor was still sensitive to
treatment with afatinib. Over time, ampliﬁcation of c-Met
led to tertiary and ﬁnal resistance. Unfortunately clinical
deterioration did not allow starting additional treatment
with c-Met inhibitors.
Molecular analyses of the tumor showed that at every
point in time the clinical response of the tumor to EGFR
inhibitors could be explained by the results of the genetic
analyses. Treatment decisions that are based on molecular
evidence result in the respective cellular and correspond-
ingly also clinical responses. Therefore, both biopsies and
re-biopsies are essential. Although the role of T790M as a
negative predictive marker for ﬁrst generation EGFR-TKI is
controversial [7] there is some evidence that patients with
de novo T790M proﬁt less from erlotinib treatment and have
a signiﬁcantly shorter progression free survival than T790
wild type patients [8,9]. Thus early molecular screening for
T790M might help to choose drugs that are speciﬁcally
effective even when a T790M mutation is present.Direct binding assays showed that in T790M not steric
blockade but increased ATP afﬁnity is the primary mechan-
ism for resistance against ATP-competitive kinase inhibitors
[10]. Correspondingly, reversible inhibitors such as erlotinib
or geﬁtinib retain some but very limited efﬁcacy in T790M
mutants, whereas irreversible inhibitors like afatinib have
been shown to overcome this resistance through covalent
binding in preclinical assays [11]. Despite the poor in vitro
activity of reversible TKIs against T790M mutants some
clinical evidence exists that reintroduction of a ﬁrst gen-
eration EGFR-TKI like erlotinib may again be effective after
occurrence of a resistance mutation, even independently of
intermittent chemotherapy [12]. Evidence based data for
this situation are still limited and in the absence of phase
3 studies retrospective papers report results only for low
patient numbers [12]. However, as retreatment efﬁcacy has
been documented even for erlotinib and geﬁtinib, we
hypothesized that an experimental treatment employing
an EGFR-TKI with added efﬁcacy such as afatinib might be a
very promising approach, and that further clinical investiga-
tions are warranted to clarify the role of irreversible EGFR-
TKIs in T790M mutated NSCLC.
Besides the T790M mutation, upregulation of HER2 has
been shown by Takezawa et al. to be another mechanism of
resistance to reversible EGFR-TKIs [13]. HER2 status was not
determined in our patient, but according to the ﬁndings of
Takezawa et al. it should be considered that the efﬁcacy of
afatinib after failure of the reversible EGFR-TKI may also be
in part due to its ability to irreversibly block the entire ErbB
family which also includes HER2 [4]. Although T790M, as a
secondary mutation after initial EGFR-TKI success, is con-
sidered a mutation with less impact on the remaining
overall survival time than some other resistance mechan-
isms e.g. cMET ampliﬁcation [14], progressive disease still
occurs and is associated with more tumor lesions, patient
J. Stoehlmacher-Williams et al.4complaints and impaired quality of life. All in all, treatment
beneﬁts may or may not include additional life time gain,
but what impressed us most was the gain in quality of life
our patient experienced. This observation is supported by
results of the Phase IIb/III LUX-Lung 1 trial which investi-
gated afatinib versus placebo in patients with advanced,
metastatic lung adenocarcinoma after failure of one or two
lines of chemotherapy and reversible EGFR TKI [15]. The
LUX-Lung 1 study was negative for its primary endpoint
(overall survival: HR 1.08, p=0.74). However, patients in
the afatinib arm experienced a signiﬁcant delay in disease
progression (median PFS was 3.3 month for afatinib vs.
1.1 month for placebo; HR 0.38, po0.0001) and signiﬁcant
improvements in NSCLC-related symptoms (cough, dyspnea,
and pain), global quality of life, and physical functioning
[15,16]. In the case presented here our patient was free of
pain and side effects, she felt full of energy and was able to
interact with her family and friends without restrictions for
the whole treatment duration with afatinib over 11 months.
She was even able to go on holidays despite having end
stage lung cancer.4. Conclusion
The palliative treatment with afatinib was deﬁnitely a
success, lasting for almost another year.
It is also worth to mention that this treatment success in
ﬁfth line was not achieved by multiple drug combinations
but using a simple oral monotherapy which was adminis-
tered by the patient herself, at home.
Despite their invasive nature we believe that it is highly
important and warranted to take rebiopsies at the time of
progression in NSCLC. Since the molecular proﬁle may
change under targeted therapy and the number of new
molecular targeted therapeutic options is rising, we believe
that the possibility of a new treatment prevails the risk of
an invasive rebiopsy. It is a major challenge of the future
that we strive to convince our patients of the need to have
rebiopsies taken in the appropriate situations.
All in all, our case critically underlines the value of
rebiopsies and timely molecular diagnostics to deliver
appropriate therapies after development of resistance to
targeted therapies with EGFR-TKIs.Conﬂict of interest statement
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